Cardiovascular Healthcare Value-Based Care Models Market Size, Trends & Growth Opportunity By Model Type (ACO, Bundled Payment, Capitation, Shared Savings, Direct Contracting), By Service Line (Interventional Cardiology, Electrophysiology, Heart Failure Management, Preventive Cardiology, Cardiac Imaging), By Payor Type (Medicare, Commercial, Medicaid, Self-Funded), By Provider Type (Independent Groups, Hospital-Employed Networks, IDNs, MSOs), By Risk Model (Upside-Only, Two-Sided, Full Capitation), By Technology Integration (RPM, AI Risk Stratification, EHR Platforms, Claims Analytics), By Region and Forecast Till 2030

Report ID : AMR1005774 | Industries : Healthcare | Published On :July 2026 | Page Count : 236

Request Sample
Ask for Customization

The U.S. cardiovascular healthcare value-based care models market is valued at USD 14.8 billion in 2025 and is projected to reach USD 27.6 billion by 2030, expanding at a compound annual growth rate of 13.2% across the forecast period. This market captures the dollar volume of cardiology services delivered and reimbursed through accountable care organizations, bundled payment arrangements, capitation contracts, shared savings structures, and CMS direct contracting initiatives rather than traditional fee-for-service billing.

Cardiovascular disease remains one of the largest single categories of U.S. healthcare spending, and payors have identified cardiology as a priority specialty for value-based redesign because a small number of high-cost episodes, such as percutaneous coronary intervention and coronary artery bypass grafting, drive an outsized share of total cardiac spend. Shifting these episodes into structured, outcomes-linked payment arrangements gives payors and providers a shared mechanism for controlling cost while protecting or improving clinical quality.

The precise mechanics behind these arrangements, from accountable care organization design to value-based payment and risk-sharing models, vary considerably depending on which party bears financial risk and how savings are shared, and they form the foundation for how the rest of this market is structured.

Core Market Snapshot

Metric

Value

Market Size (2025)

USD 14.8 Billion

Forecast Size (2030)

USD 27.6 Billion

CAGR (2025-2030)

13.2%

Base Year

2025

Forecast Period

2025-2030 (5-year)

Largest Model Type

Accountable Care Organizations (ACO) - 34% of market

Fastest Growing Model Type

Direct Contracting / REACH Models - 16.8% CAGR

Largest Service Line

Interventional Cardiology (PCI, Stents) - 29% of market

Fastest Growing Service Line

Heart Failure Management Programs - 15.4% CAGR

Largest Payor Type

Medicare (Traditional + Medicare Advantage) - 48% of market

Largest Provider Type

Hospital-Employed Cardiology Networks - 38% of market

Largest Region

Northeast - 27% of market

Fastest Growing Region

Southeast - 14.6% CAGR

Market Structure

Moderately consolidated (Top 3 organizations: approximately 34% share)

Number of Major Players

8-10 national platforms plus 15-20 regional and specialty cardiology platforms

 

Market Dynamics: Drivers, Restraints & Opportunities

Growth in this market is being driven by three converging forces. First, the Centers for Medicare & Medicaid Services has continued to expand mandatory and voluntary episode-based programs, including the 2026 Transforming Episode Accountability Model, which places cardiac surgical episodes such as CABG inside mandatory bundles across hundreds of hospitals. Second, Medicare Advantage penetration has passed the halfway mark of Medicare beneficiaries, and MA plans are structurally predisposed to push specialty risk down to provider organizations. Third, an aging population with rising rates of heart failure and atrial fibrillation is increasing the volume of chronic cardiovascular spend that both payors and providers want to manage proactively rather than reactively.

These drivers create a genuine strategic dilemma for cardiology groups. Practices that lack the data infrastructure to manage risk are exposed to downside losses under two-sided contracts, while practices that build strong care coordination and analytics capabilities can capture disproportionate shared-savings upside. This bifurcation is why technology adoption, not just contract signing, is becoming the deciding factor in which organizations thrive under value-based cardiology arrangements.

Restraints include the operational burden of quality reporting, fragmented electronic health record systems across referring physicians, and the reluctance of some independent cardiology groups to accept downside risk without proven technology-enabled care coordination platforms already in place. Opportunities are concentrated in preventive cardiology and remote monitoring, where early intervention economics align cleanly with shared-savings incentives.

Our deeper market dynamics analysis quantifies each driver, restraint, and opportunity by weighted contribution to forecast growth and cross-references them against payor and provider adoption timelines, information that goes well beyond the directional view presented here.

Market Segmentation Overview

The market is segmented across six dimensions that together describe how cardiovascular value-based care is structured, delivered, and financed: value-based care model type, cardiovascular service line, payor type, provider type, risk model structure, and technology integration.

Accountable care organizations represent the largest model type at 34% of the market, reflecting the scale of Medicare Shared Savings Program and ACO REACH participation among cardiology-affiliated provider groups. Bundled payment models tied to discrete cardiac episodes account for 22% of the market, followed by capitation-based cardiology arrangements at 18%, shared savings and shared risk contracts at 16%, and CMS direct contracting and REACH structures at 10%, the segment growing fastest at 16.8% CAGR as CMS continues to favor total-cost-of-care accountability over episodic bundles alone.

On the clinical side, interventional cardiology commands the largest service-line share at 29% given the volume and cost concentration of PCI procedures, while heart failure management programs are the fastest-growing cardiovascular service line applications at 15.4% CAGR, driven by remote monitoring-enabled readmission reduction programs. Electrophysiology, preventive cardiology, and cardiac imaging make up the remaining service-line mix.

Medicare, spanning traditional fee-for-service beneficiaries attributed to ACOs and Medicare Advantage members in risk-based cardiology arrangements, accounts for 48% of the market. Commercial insurers represent 29%, Medicaid managed care 14%, and self-funded employer plans the remaining 9%. On the provider side, hospital-employed cardiology networks lead at 38% of market activity, ahead of integrated delivery networks at 26%, independent cardiology groups at 24%, and specialty care platforms or MSOs at 12%.

Each of these segmentation dimensions, along with the risk-model and technology-integration breakdowns, carries its own adoption trajectory and buyer profile. Our full segmentation dataset quantifies sub-segment revenue, five-year CAGR, and competitive concentration at a level of granularity not published here.

Regional & State-Level Snapshot

Regional distribution of cardiovascular value-based care activity closely tracks the geographic footprint of large integrated delivery networks and Medicare Advantage penetration. The Northeast leads the market at approximately 27% share, anchored by dense hospital-employed cardiology networks in Pennsylvania, New York, and New Jersey and mature ACO participation in metropolitan markets such as Philadelphia.

The Southeast follows at roughly 24% of the market and is the fastest-growing region at 14.6% CAGR, driven by high cardiovascular disease prevalence, expanding Medicare Advantage enrollment in Florida and Georgia, and the physician-led VBC platforms that have concentrated growth strategies in metropolitan areas including Miami and Atlanta. The Midwest holds approximately 19% share, led by activity in Illinois and Ohio, while the Southwest, anchored by Texas, accounts for roughly 16%. The West, led by California and Arizona, represents the remaining 14%, with Los Angeles and Phoenix standing out as concentrated metropolitan markets for cardiology risk contracting.

State-level intensity generally correlates with which payor and provider landscape in cardiovascular VBC is locally dominant. Markets with a high concentration of Medicare Advantage enrollment and hospital-employed cardiology groups tend to move toward two-sided risk fastest, while markets with fragmented independent practices adopt upside-only arrangements first.

City-level and state-level market sizing down to the metropolitan statistical area, including Philadelphia, New York, Miami, Atlanta, Chicago, Dallas, Los Angeles, and Phoenix, is available in the complete regional breakdown within the full report.

Competitive Landscape Snapshot

The competitive landscape spans national payor-led platforms, physician-led value-based care enablers, and cardiology-specialized platforms. National payors including Optum, CVS Health, Humana, and Kaiser Permanente operate the broadest cardiology risk footprints, largely through Medicare Advantage-aligned provider networks and owned or affiliated primary care and specialty assets.

Physician-led platforms such as ChenMed, Oak Street Health, agilon health, ApolloMed, and Aledade have built scale by enabling independent and community-based physicians to take on risk without selling their practices outright, while cardiology-specialized organizations, led by Cardiovascular Associates of America, along with Privia Health and Evolent Health, focus more narrowly on structuring risk arrangements specifically around cardiac episodes and specialty care coordination.

Market structure is moderately consolidated, with the top three organizations controlling an estimated 34% combined share. A complete view of positioning, named-entity profiles, and strategic posture for all twelve organizations covered in this study, including leading companies in cardiovascular value-based care, is available as a dedicated resource.

Detailed competitive benchmarking metrics, including market share by model type, reimbursement structure comparisons, and provider network scale, are reserved for the complete report and are not disclosed at this summary level.

Frequently Asked Questions

The market is valued at USD 14.8 billion in 2025 and is projected to reach USD 27.6 billion by 2030, growing at a CAGR of 13.2% as CMS programs and Medicare Advantage plans continue shifting cardiology reimbursement away from fee-for-service.

Accountable care organizations hold the largest share at approximately 34%, reflecting broad participation by cardiology-affiliated provider groups in Medicare Shared Savings Program and ACO REACH structures.

Heart failure management programs are the fastest-growing service line at approximately 15.4% CAGR, supported by remote monitoring technology that reduces avoidable readmissions under shared-savings and two-sided risk contracts.

Medicare, combining traditional fee-for-service beneficiaries attributed to ACOs and Medicare Advantage members in risk arrangements, accounts for roughly 48% of market activity, the largest of any payor category.

The Northeast leads with approximately 27% share, reflecting dense hospital-employed cardiology networks and mature ACO participation in states such as Pennsylvania, New York, and New Jersey.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. United States Cardiovascular Healthcare Value-Based Care Models Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.4. Restraints

3.5. Opportunities

3.6. Porters Five Force Model

3.7. Value Chain Analysis

4. U.S. Cardiovascular Healthcare Value-Based Care Models Market, By Value-Based Care Model Type

4.1. Accountable Care Organizations (ACO) – Cardiology Participation Models

4.2. Bundled Payment Models (e.g., PCI, CABG Episodes)

4.3. Capitation-Based Cardiology Care

4.4. Shared Savings & Shared Risk Contracts

4.5. Direct Contracting / REACH Models (CMS Initiatives)

5. U.S. Cardiovascular Healthcare Value-Based Care Models Market, By Cardiovascular Service Line

5.1. Interventional Cardiology (PCI, Stents)

5.2. Electrophysiology (AFib, Device Implantation)

5.3. Heart Failure Management Programs

5.4. Preventive Cardiology & Chronic Disease Management

5.5. Cardiac Imaging & Diagnostics

6. U.S. Cardiovascular Healthcare Value-Based Care Models Market, By Payor Type

6.1. Medicare (Traditional + Medicare Advantage)

6.2. Commercial Insurers

6.3. Medicaid Managed Care

6.4. Self-Funded Employer Plans

7. U.S. Cardiovascular Healthcare Value-Based Care Models Market, By Provider Type

7.1. Independent Cardiology Groups (e.g., CVAUSA Affiliates)

7.2. Hospital-Employed Cardiology Networks

7.3. Integrated Delivery Networks (IDNs)

7.4. Specialty Care Platforms / MSOs

8. U.S. Cardiovascular Healthcare Value-Based Care Models Market, By Risk Model Structure

8.1. Upside-Only Risk Models

8.2. Two-Sided Risk Models

8.3. Full Capitation / Global Budget Models

9. U.S. Cardiovascular Healthcare Value-Based Care Models Market, By Technology Integration

9.1. Remote Patient Monitoring (RPM)

9.2. AI-Driven Risk Stratification

9.3. EHR-Integrated Care Coordination Platforms

9.4. Claims Analytics & Utilization Management Systems

10. United States Cardiovascular Healthcare Value-Based Care Models Market Analysis and Forecast (2026–2030)

10.1. Introduction

10.2. Market Share Analysis

10.3. Market Size and Forecast

10.4. Market Size and Forecast, By Geography

10.4.1. Northeast

10.4.1.1. Market Share Analysis

10.4.1.2. Market Size and Forecast

10.4.1.3. Market Size and Forecast, By Geography

10.4.1.3.1. Pennsylvania

10.4.1.3.1.1. Market Share Analysis

10.4.1.3.1.2. Market Size and Forecast

10.4.1.3.1.3. Market Size and Forecast, By Geography

10.4.1.3.1.3.1. Philadelphia

10.4.1.3.1.3.1.1. Market Share Analysis

10.4.1.3.1.3.1.2. Market Size and Forecast

10.4.1.3.1.3.1.3. By Product

10.4.1.3.1.3.1.4. By Technology

10.4.1.3.1.3.1.5. By Application

10.4.1.3.1.3.1.6. By Customer

10.4.1.3.2. New York

10.4.1.3.2.1. Market Share Analysis

10.4.1.3.2.2. Market Size and Forecast

10.4.1.3.2.3. By Product

10.4.1.3.2.4. By Technology

10.4.1.3.2.5. By Application

10.4.1.3.2.6. By Customer

10.4.1.3.3. New Jersey

10.4.1.3.3.1. Market Share Analysis

10.4.1.3.3.2. Market Size and Forecast

10.4.1.3.3.3. By Product

10.4.1.3.3.4. By Technology

10.4.1.3.3.5. By Application

10.4.1.3.3.6. By Customer

10.4.2. Southeast

10.4.2.1. Market Share Analysis

10.4.2.2. Market Size and Forecast

10.4.2.3. Market Size and Forecast, By Geography

10.4.2.3.1. Florida

10.4.2.3.1.1. Market Share Analysis

10.4.2.3.1.2. Market Size and Forecast

10.4.2.3.1.3. Market Size and Forecast, By Geography

10.4.2.3.1.3.1. Miami

10.4.2.3.1.3.1.1. Market Share Analysis

10.4.2.3.1.3.1.2. Market Size and Forecast

10.4.2.3.1.3.1.3. By Product

10.4.2.3.1.3.1.4. By Technology

10.4.2.3.1.3.1.5. By Application

10.4.2.3.1.3.1.6. By Customer

10.4.2.3.2. Georgia

10.4.2.3.2.1. Market Share Analysis

10.4.2.3.2.2. Market Size and Forecast

10.4.2.3.2.3. Market Size and Forecast, By Geography

10.4.2.3.2.3.1. Atlanta

10.4.2.3.2.3.1.1. Market Share Analysis

10.4.2.3.2.3.1.2. Market Size and Forecast

10.4.2.3.2.3.1.3. By Product

10.4.2.3.2.3.1.4. By Technology

10.4.2.3.2.3.1.5. By Application

10.4.2.3.2.3.1.6. By Customer

10.4.2.3.3. North Carolina

10.4.2.3.3.1. Market Share Analysis

10.4.2.3.3.2. Market Size and Forecast

10.4.2.3.3.3. By Product

10.4.2.3.3.4. By Technology

10.4.2.3.3.5. By Application

10.4.2.3.3.6. By Customer

10.4.3. Midwest

10.4.3.1. Market Share Analysis

10.4.3.2. Market Size and Forecast

10.4.3.3. Market Size and Forecast, By Geography

10.4.3.3.1. Illinois

10.4.3.3.1.1. Market Share Analysis

10.4.3.3.1.2. Market Size and Forecast

10.4.3.3.1.3. Market Size and Forecast, By Geography

10.4.3.3.1.3.1. Chicago

10.4.3.3.1.3.1.1. Market Share Analysis

10.4.3.3.1.3.1.2. Market Size and Forecast

10.4.3.3.1.3.1.3. By Product

10.4.3.3.1.3.1.4. By Technology

10.4.3.3.1.3.1.5. By Application

10.4.3.3.1.3.1.6. By Customer

10.4.3.3.2. Ohio

10.4.3.3.2.1. Market Share Analysis

10.4.3.3.2.2. Market Size and Forecast

10.4.3.3.2.3. By Product

10.4.3.3.2.4. By Technology

10.4.3.3.2.5. By Application

10.4.3.3.2.6. By Customer

10.4.4. Southwest

10.4.4.1. Market Share Analysis

10.4.4.2. Market Size and Forecast

10.4.4.3. Market Size and Forecast, By Geography

10.4.4.3.1. Texas

10.4.4.3.1.1. Market Share Analysis

10.4.4.3.1.2. Market Size and Forecast

10.4.4.3.1.3. Market Size and Forecast, By Geography

10.4.4.3.1.3.1. Dallas

10.4.4.3.1.3.1.1. Market Share Analysis

10.4.4.3.1.3.1.2. Market Size and Forecast

10.4.4.3.1.3.1.3. By Product

10.4.4.3.1.3.1.4. By Technology

10.4.4.3.1.3.1.5. By Application

10.4.4.3.1.3.1.6. By Customer

10.4.5. West

10.4.5.1. Market Share Analysis

10.4.5.2. Market Size and Forecast

10.4.5.3. Market Size and Forecast, By Geography

10.4.5.3.1. California

10.4.5.3.1.1. Market Share Analysis

10.4.5.3.1.2. Market Size and Forecast

10.4.5.3.1.3. Market Size and Forecast, By Geography

10.4.5.3.1.3.1. Los Angeles

10.4.5.3.1.3.1.1. Market Share Analysis

10.4.5.3.1.3.1.2. Market Size and Forecast

10.4.5.3.1.3.1.3. By Product

10.4.5.3.1.3.1.4. By Technology

10.4.5.3.1.3.1.5. By Application

10.4.5.3.1.3.1.6. By Customer

10.4.5.3.2. Arizona

10.4.5.3.2.1. Market Share Analysis

10.4.5.3.2.2. Market Size and Forecast

10.4.5.3.2.3. Market Size and Forecast, By Geography

10.4.5.3.2.3.1. Phoenix

10.4.5.3.2.3.1.1. Market Share Analysis

10.4.5.3.2.3.1.2. Market Size and Forecast

10.4.5.3.2.3.1.3. By Product

10.4.5.3.2.3.1.4. By Technology

10.4.5.3.2.3.1.5. By Application

10.4.5.3.2.3.1.6. By Customer

11. Buyer Intelligence & Demand Landscape

11.1. Buyer Segmentation

11.1.1. Government Payors (CMS)

11.1.2. Commercial Insurers

11.1.3. Employer-Sponsored Health Plans

11.2. Buyer Industries

11.2.1. Health Insurance Providers

11.2.2. Employer Healthcare Procurement

11.3. Buyer Company Types

11.3.1. National Insurers

11.3.2. Regional Payors

11.3.3. TPAs

11.4. Region-wise Buyer Mapping Across U.S. States

11.5. Demand Clusters

11.5.1. Medicare Advantage-Heavy Regions

11.5.2. High Cardiovascular Disease Prevalence Zones

11.6. Buyer Scale Classification

11.6.1. National vs Regional Insurers

11.7. Procurement Models

11.7.1. Risk-Sharing Contracts

11.7.2. Episode-Based Reimbursements

11.8. Buying Triggers

11.8.1. Cost Reduction Mandates

11.8.2. CMS Policy Changes

11.9. Decision-Makers

11.9.1. Chief Medical Officers

11.9.2. VP of Network Contracting

11.9.3. Payor Relations Heads

11.10. Budget Ownership

11.10.1. Health Plan Finance & Actuarial Teams

11.11. Vendor Selection Criteria

11.11.1. Outcome Improvement Capability

11.11.2. Cost Reduction Evidence

11.11.3. Data/Reporting Infrastructure

11.12. Contract Value Bands

11.12.1. Per-Member-Per-Month (PMPM)

11.12.2. Episode-Based Reimbursements

11.13. Sales Cycle

11.13.1. 6–18 Months (Contract Negotiation Cycles)

11.14. Strategic Relevance

11.14.1. Direct Alignment with CVAUSA's Payer Contracting and Expansion Strategy

12. Competition Analysis

12.1. Market Positioning Overview

12.1.1. National vs Regional Cardiology Platforms

12.1.2. Hospital-Led vs Physician-Led VBC Models

12.1.3. Pricing Models Tied to Outcomes vs Volume

12.1.4. Technology-Enabled Care Differentiation

12.2. Competitive Benchmarking Metrics

12.2.1. Market Share (Cardiology VBC Participation)

12.2.2. Pricing/Reimbursement Models

12.2.3. Geographic Coverage

12.2.4. Provider Network Scale

12.2.5. Care Coordination Capabilities

12.2.6. Certifications & CMS Program Participation

12.3. Strategic Moves

12.3.1. Expansion of Cardiology-Focused ACOs

12.3.2. Partnerships with Medicare Advantage Plans

12.3.3. Acquisitions of Cardiology Practices

12.3.4. Investments in RPM and Analytics Platforms

12.4. Competitive Mapping & Gaps

12.4.1. Underserved Independent Cardiology Groups

12.4.2. Limited Specialization in Cardiovascular VBC vs General ACOs

12.4.3. White-Space in Preventive Cardiology Programs

12.4.4. Opportunity for CVAUSA

12.4.4.1. Scale Physician-Led Cardiology VBC Networks

12.4.4.2. Strengthen Payer Partnerships in High-MA Regions

13. Company Profiles

13.1. Optum

13.1.1. Overview

13.1.2. Geographic Footprint

13.1.3. Service Portfolio

13.1.4. Customer Segments

13.1.5. GTM Strategy

13.1.6. Financials

13.1.7. Certifications

13.1.8. Partnerships

13.1.9. R&D

13.1.10. Recent Developments

13.1.11. SWOT

13.2. CVS Health

13.2.1. Overview

13.2.2. Geographic Footprint

13.2.3. Service Portfolio

13.2.4. Customer Segments

13.2.5. GTM Strategy

13.2.6. Financials

13.2.7. Certifications

13.2.8. Partnerships

13.2.9. R&D

13.2.10. Recent Developments

13.2.11. SWOT

13.3. Humana

13.3.1. Overview

13.3.2. Geographic Footprint

13.3.3. Service Portfolio

13.3.4. Customer Segments

13.3.5. GTM Strategy

13.3.6. Financials

13.3.7. Certifications

13.3.8. Partnerships

13.3.9. R&D

13.3.10. Recent Developments

13.3.11. SWOT

13.4. Kaiser Permanente

13.4.1. Overview

13.4.2. Geographic Footprint

13.4.3. Service Portfolio

13.4.4. Customer Segments

13.4.5. GTM Strategy

13.4.6. Financials

13.4.7. Certifications

13.4.8. Partnerships

13.4.9. R&D

13.4.10. Recent Developments

13.4.11. SWOT

13.5. ChenMed

13.5.1. Overview

13.5.2. Geographic Footprint

13.5.3. Service Portfolio

13.5.4. Customer Segments

13.5.5. GTM Strategy

13.5.6. Financials

13.5.7. Certifications

13.5.8. Partnerships

13.5.9. R&D

13.5.10. Recent Developments

13.5.11. SWOT

13.6. Oak Street Health

13.6.1. Overview

13.6.2. Geographic Footprint

13.6.3. Service Portfolio

13.6.4. Customer Segments

13.6.5. GTM Strategy

13.6.6. Financials

13.6.7. Certifications

13.6.8. Partnerships

13.6.9. R&D

13.6.10. Recent Developments

13.6.11. SWOT

13.7. Cardiovascular Associates of America

13.7.1. Overview

13.7.2. Geographic Footprint

13.7.3. Service Portfolio

13.7.4. Customer Segments

13.7.5. GTM Strategy

13.7.6. Financials

13.7.7. Certifications

13.7.8. Partnerships

13.7.9. R&D

13.7.10. Recent Developments

13.7.11. SWOT

13.8. Privia Health

13.8.1. Overview

13.8.2. Geographic Footprint

13.8.3. Service Portfolio

13.8.4. Customer Segments

13.8.5. GTM Strategy

13.8.6. Financials

13.8.7. Certifications

13.8.8. Partnerships

13.8.9. R&D

13.8.10. Recent Developments

13.8.11. SWOT

13.9. agilon health

13.9.1. Overview

13.9.2. Geographic Footprint

13.9.3. Service Portfolio

13.9.4. Customer Segments

13.9.5. GTM Strategy

13.9.6. Financials

13.9.7. Certifications

13.9.8. Partnerships

13.9.9. R&D

13.9.10. Recent Developments

13.9.11. SWOT

13.10. Evolent Health

13.10.1. Overview

13.10.2. Geographic Footprint

13.10.3. Service Portfolio

13.10.4. Customer Segments

13.10.5. GTM Strategy

13.10.6. Financials

13.10.7. Certifications

13.10.8. Partnerships

13.10.9. R&D

13.10.10. Recent Developments

13.10.11. SWOT

13.11. ApolloMed

13.11.1. Overview

13.11.2. Geographic Footprint

13.11.3. Service Portfolio

13.11.4. Customer Segments

13.11.5. GTM Strategy

13.11.6. Financials

13.11.7. Certifications

13.11.8. Partnerships

13.11.9. R&D

13.11.10. Recent Developments

13.11.11. SWOT

13.12. Aledade

13.12.1. Overview

13.12.2. Geographic Footprint

13.12.3. Service Portfolio

13.12.4. Customer Segments

13.12.5. GTM Strategy

13.12.6. Financials

13.12.7. Certifications

13.12.8. Partnerships

13.12.9. R&D

13.12.10. Recent Developments

13.12.11. SWOT

Frequently Asked Questions

The market is valued at USD 14.8 billion in 2025 and is projected to reach USD 27.6 billion by 2030, growing at a CAGR of 13.2% as CMS programs and Medicare Advantage plans continue shifting cardiology reimbursement away from fee-for-service.

Accountable care organizations hold the largest share at approximately 34%, reflecting broad participation by cardiology-affiliated provider groups in Medicare Shared Savings Program and ACO REACH structures.

Heart failure management programs are the fastest-growing service line at approximately 15.4% CAGR, supported by remote monitoring technology that reduces avoidable readmissions under shared-savings and two-sided risk contracts.

Medicare, combining traditional fee-for-service beneficiaries attributed to ACOs and Medicare Advantage members in risk arrangements, accounts for roughly 48% of market activity, the largest of any payor category.

The Northeast leads with approximately 27% share, reflecting dense hospital-employed cardiology networks and mature ACO participation in states such as Pennsylvania, New York, and New Jersey.

Inquire Before Buying Request Free Sample Ask For Discount

This report covers the U.S. cardiovascular healthcare value-based care models market across the 2025 base year through a 2030 forecast horizon, segmented by value-based care model type, cardiovascular service line, payor type, provider type, risk model structure, technology integration, and region.

Public market forecasts: Base-year sizing was cross-referenced against multiple published estimates for the broader U.S. value-based healthcare services category, then narrowed to the cardiovascular specialty using CMS program participation data and cardiovascular disease spending share, since no single published source isolates a cardiology-specific value-based care figure.

Adjacent-market disclosures: CMS Innovation Center program data, including historical episode payment model hospital counts and the 2026 Transforming Episode Accountability Model participant scope, together with payor investor disclosures on value-based patient attribution, were used as lower-bound and upper-bound cross-checks on cardiology-specific program scale.

Segment-share derivation: Model-type, service-line, payor-type, and provider-type shares were derived by applying documented differentials, such as relative ACO REACH versus bundled-payment program scale and Medicare Advantage risk-contracting intensity, to the triangulated base estimate, then validated for internal consistency.

Regional cross-check: State and regional shares were checked against independent regional healthcare spending and Medicare Advantage penetration breakdowns and adjusted to reflect the specific cardiology value-based care scope of this report rather than general healthcare spending patterns.

Frequently Asked Questions

The market is valued at USD 14.8 billion in 2025 and is projected to reach USD 27.6 billion by 2030, growing at a CAGR of 13.2% as CMS programs and Medicare Advantage plans continue shifting cardiology reimbursement away from fee-for-service.

Accountable care organizations hold the largest share at approximately 34%, reflecting broad participation by cardiology-affiliated provider groups in Medicare Shared Savings Program and ACO REACH structures.

Heart failure management programs are the fastest-growing service line at approximately 15.4% CAGR, supported by remote monitoring technology that reduces avoidable readmissions under shared-savings and two-sided risk contracts.

Medicare, combining traditional fee-for-service beneficiaries attributed to ACOs and Medicare Advantage members in risk arrangements, accounts for roughly 48% of market activity, the largest of any payor category.

The Northeast leads with approximately 27% share, reflecting dense hospital-employed cardiology networks and mature ACO participation in states such as Pennsylvania, New York, and New Jersey.

Inquire Before Buying Request Free Sample Ask For Discount